First Turn Management LLC Has $30.98 Million Stock Position in United Therapeutics Corporation $UTHR

First Turn Management LLC trimmed its position in United Therapeutics Corporation (NASDAQ:UTHR) by 25.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 63,580 shares of the biotechnology company’s stock after selling 21,738 shares during the period. United Therapeutics comprises approximately 3.5% of First Turn Management LLC’s holdings, making the stock its 12th largest holding. First Turn Management LLC’s holdings in United Therapeutics were worth $30,979,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Clearstead Advisors LLC boosted its holdings in shares of United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after buying an additional 23 shares during the period. Independent Advisor Alliance boosted its holdings in shares of United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after buying an additional 27 shares during the period. Florida Financial Advisors LLC boosted its holdings in shares of United Therapeutics by 5.4% in the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after buying an additional 28 shares during the period. NDVR Inc. boosted its holdings in shares of United Therapeutics by 5.1% in the fourth quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock worth $300,000 after buying an additional 30 shares during the period. Finally, Principal Securities Inc. boosted its holdings in shares of United Therapeutics by 4.7% in the fourth quarter. Principal Securities Inc. now owns 686 shares of the biotechnology company’s stock worth $334,000 after buying an additional 31 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. UBS Group raised their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. HC Wainwright raised their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Raymond James Financial assumed coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Finally, Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Price Performance

NASDAQ UTHR opened at $545.96 on Friday. The company has a 50 day simple moving average of $566.75 and a 200-day simple moving average of $521.34. The firm has a market capitalization of $23.17 billion, a price-to-earnings ratio of 20.15, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the company earned $6.63 earnings per share. On average, analysts predict that United Therapeutics Corporation will post 26.84 EPS for the current year.

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $547.07, for a total value of $4,540,681.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $24,712,246.04. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $545.83, for a total transaction of $5,185,385.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,113,210.79. This trade represents a 19.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 634,984 shares of company stock valued at $358,175,202 over the last three months. 8.60% of the stock is owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.